A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.
Marks
Randolph S
RS
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Graham
David L
DL
Sloan
Jeff A
JA
Hillman
Shauna
S
Fishkoff
Steven
S
Krook
James E
JE
Okuno
Scott H
SH
Mailliard
James A
JA
Fitch
Tom R
TR
Addo
Ferdinand
F
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D047630:Depsipeptides; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011788:Quality of Life
D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; C075610:dolastatin 15; C094621:cemadotin